NBTX vs SNY
Nanobiotix S.a. and Sanofi, side by side — 8 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | NBTX | SNY |
|---|---|---|
| Revenue | €32.6M | €43.6B |
| Net income | €-24.0M | €7.8B |
| Gross margin | · | 77.2% |
| Net margin | −73.5% | 18.0% |
| Return on equity | · | 10.5% |
| Diluted EPS | −€0.50 | €6.37 |
| Dividend / share | · | €3.92 |
| Payout ratio | · | 61.1% |
| Free cash flow | €-34.0M | · |
| Equity | · | €71.4B |
| Net debt / equity | · | 0.15× |
| Current ratio | 1.09× | 1.09× |
| Revenue CAGR 5y | 67.0% | 3.9% |
| Profit CAGR 5y | · | −8.7% |
SNY bills 1338.5× the revenue of NBTX, and NBTX closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
8 years side by side
| Fiscal year | NBTX | SNY |
|---|---|---|
| FY2025 | €32.6M | €43.6B |
| FY2024 | €-7.2M | €41.1B |
| FY2023 | €36.2M | €37.8B |
| FY2022 | €4.8M | €37.7B |
| FY2021 | €2.6M | €37.8B |
| FY2020 | €2.5M | €36.0B |
| FY2019 | €2.5M | €36.1B |
| FY2018 | €3.5M | €34.5B |
Bottom line
| Fiscal year | NBTX | SNY |
|---|---|---|
| FY2025 | €-24.0M | €7.8B |
| FY2024 | €-68.1M | €5.6B |
| FY2023 | €-39.7M | €5.4B |
| FY2022 | €-57.0M | €8.4B |
| FY2021 | €-47.1M | €6.2B |
| FY2020 | €-33.6M | €12.3B |
| FY2019 | €-50.9M | €2.8B |
| FY2018 | €-30.3M | €4.3B |
8 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −€43,593,407,000 | SNY |
| FY2024 | −€41,088,191,000 | SNY |
| FY2023 | −€37,780,793,000 | SNY |
| FY2022 | −€37,646,224,000 | SNY |
| FY2021 | −€37,758,353,000 | SNY |
| FY2020 | −€36,038,488,000 | SNY |
| FY2019 | −€36,123,459,000 | SNY |
| FY2018 | −€34,459,521,000 | SNY |
SNY has reported the higher revenue in every one of these 8 fiscal years. The gap has widened since the earliest year compared.
8 of 11 comparable fiscal years — a year missing data on either side is not counted.
5 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −91.5 pp | SNY |
| FY2023 | −124.0 pp | SNY |
| FY2022 | −1216.0 pp | SNY |
| FY2020 | −1371.4 pp | SNY |
| FY2018 | −885.0 pp | SNY |
SNY has kept the higher net margin in every one of these 5 fiscal years.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NBTX's net margin has been more volatile than SNY's over the 5 comparable fiscal years — 532.7 percentage points of standard deviation against 7.7.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
SNY led in net margin in every one of the 5 comparable fiscal years — a structural lead, not a recent swing.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.